Home Newsfeeds EF Hutton Reiterates Buy on Tetra Technologies, Maintains $8.5 Price Target

EF Hutton Reiterates Buy on Tetra Technologies, Maintains $8.5 Price Target

EF Hutton analyst Tim Moore reiterates Tetra Technologies (NYSE:TTI) with a Buy and maintains $8.5 price target.

byBenzinga Newsdesk

March 1, 2023

1 minute read

EF Hutton analyst Tim Moore reiterates Tetra Technologies (NYSE:TTI) with a Buy and maintains $8.5 price target.

Microsoft Marks Its Largest UK Investment With Major Focus On AI Development

By Khyathi Dalal

November 30, 5:22 PM

After Microsoft (NASDAQ: MSFT) President Brad Smith dismissed the development of any super-intelligent Artificial Intelligence (AI) within the n

MSFT

Ethereum Falls But Remains Above This Key Level; FTX Token, Gnosis Among Top Losers

By Lisa Levin

December 5, 10:30 AM

Bitcoin (CRYPTO: BTC) moved higher, with the cryptocurrency prices trading above the $41,800 level on Tuesday.

$FTT

Cathie Wood Favorite Ginkgo Bioworks Bolsters Biosecurity Platform Via This Acquisition

By Akanksha Bakshi

August 19, 12:34 PM

Ginkgo Bioworks Holdings Inc (NYSE:DNA) has purchased certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation.…

DNA

Artelo Biosciences Announces Selection Of Worldwide Clinical Trials As Clinical Research Organization To Support First-In-Human Study Of ART26.12

By Benzinga Newsdesk

January 8, 9:47 AM

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

EF Hutton Reiterates Buy on Tetra Technologies, Maintains $8.5 Price Target

Related Posts

Microsoft Marks Its Largest UK Investment With Major Focus On AI Development

Ethereum Falls But Remains Above This Key Level; FTX Token, Gnosis Among Top Losers

Cathie Wood Favorite Ginkgo Bioworks Bolsters Biosecurity Platform Via This Acquisition

Artelo Biosciences Announces Selection Of Worldwide Clinical Trials As Clinical Research Organization To Support First-In-Human Study Of ART26.12